The responses in the ritux pilot do not look like the dara ones - someone posted them in one of these threads the other day. They are not anything like as sustained or as large.
In phase 2 ritux failed in its primary outcomes but they went ahead because of secondary stuff iirc.
I'm not saying...
I mean that F&M should have included controls in the pilot. If none of the controls had had sustained improvements like the improvers who got the drug did, we could be a good deal more confident that the results are not placebo.
Can you say anything about any more targeted projects you're aware of? All I can think of is the CA10 investigations that JEs pain colleagues are setting up.
I think @MelbME is doing a good day/bad day study?
And @jnmaciuch has mentioned wanting to do a study where blood draws are done on patients currently in PEM.
Apologies if I've got either of these wrong.
Yeah I remember isa maybe being better at depleting cd38 than dara or something? I can't remember, no spoons to look it up but I saved it somewhere.
It would be a real turn up for the books if cd19 works.
I'm glad CS seems to be moving swiftly with those trials.
I agree, this is odd. i suppose there are 2 LDN trials on going, one of which is testing pyridostigmine as well. But you would have thought if they're happy to give them to patients they would be pushing for formal trials...
So the same trigger seems to have caused the MECFS and Sjogrens. I've heard of that happening after covid too.
Perhaps there is a clue in the fact they sometimes appear together
I hadn't heard this - can Sjogrens really cause MS?
From your description it does sound like your friend has MECFS. What I find frustrating is people saying that 'we know x thing causes MECFS' without good evidence. I've not heard about MECFS being triggered by an autoimmune disease before...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.